Nasdaq:DRIO
DarioHealth Corp.
DRIO develops AI-driven medical imaging software to accelerate diagnostic precision for radiologists worldwide.
Key Metrics
Investment Thesis
Bull Case
Investors may view DRIO as a high-potential turnaround play given the rapid recovery in revenue and the massive tailwinds from global adoption of AI in radiology. The company's strong balance sheet relative to its liabilities, with significant cash reserves ($27.8M) and paid-in capital ($462.4M), provides a runway to fund R&D until profitability is achieved. If the new algorithms gain wider regulatory approval and market penetration accelerates, DRIO could capture a dominant market share in a fragmented industry with high barriers to entry.
Bear Case
The stock carries substantial downside risk due to three consecutive years of net losses totaling over $160M, which signals fundamental business model issues or severe execution failures. With total liabilities nearing half of total assets ($46.9M vs $118.9M), the company remains highly sensitive to interest rate hikes and potential credit tightening that could restrict financing options. The heavy reliance on non-operating income ($13.1M) to offset operational losses suggests that core business operations are not yet self-sustaining, making DRIO a speculative bet rather than an investment in stable earnings.
About DarioHealth Corp.
DarioHealth Corp. (DRIO) is a leading developer of next-generation AI-powered medical imaging software designed to enhance radiology workflows and improve diagnostic accuracy. The company serves hospitals and healthcare systems globally with its proprietary AI algorithms that assist in detecting and characterizing lesions across various modalities including MRI, CT, and mammography. Revenue growth in 2024 highlighted a strong recovery trajectory as the firm expanded its clinical partnerships and deployed advanced machine learning models to address unmet needs in oncology and neurology.
Analysis
Management Discussion
Despite a challenging operating environment, DRIO managed to reverse its revenue decline in 2024, returning to $27.0M after a low point in 2023, which suggests successful execution of its growth strategy. However, the company continues to burn cash with an operating loss of $57.7M and a net income deficit of $42.7M, relying heavily on financing cash flows of $38.5M to maintain liquidity. The large non-cash adjustments ($11.5M) and amortization ($6.1M) indicate that reported profitability is significantly distorted by accounting for past acquisitions rather than core operational performance.
Industry Overview
The medical AI software sector is experiencing explosive growth driven by aging populations and the urgent need to alleviate radiologist burnout through automation. Companies in this space compete on algorithm accuracy, clinical validation data, and integration capabilities with hospital Picture Archiving and Communication Systems (PACS). The industry is characterized by high regulatory hurdles from bodies like the FDA and EMA, but also offers significant pricing power once products are cleared and integrated into standard workflows.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $27.7M | $20.4M | $27.0M |
| Cost of Revenue | $18.0M | $14.4M | $13.8M |
| Gross Profit | $9.7M | $6.0M | $13.3M |
| Operating Expenses | $66.5M | $62.2M | $71.0M |
| Operating Income | $-56.8M | $-56.2M | $-57.7M |
| R&D | $19.6M | $20.2M | $24.2M |
| G&A | $16.5M | $18.1M | $20.5M |
| Stock-Based Comp | $17.0M | $19.7M | $46.0K |
| Depreciation | $356.0K | $473.0K | $1.3M |
| Amortization | $4.4M | $4.5M | $6.1M |
| Other OpEx | $30.3M | $23.8M | $26.4M |
| Non-Operating Income | $-5.4M | $-3.2M | $13.1M |
| Interest Income | $506.0K | $1.9M | $1.1M |
| Pre-Tax Income | $-62.2M | $-59.4M | $-44.6M |
| Income Tax | $4.0K | $64.0K | $-1.9M |
| Continuing Ops | $-62.2M | $-59.4M | $-42.7M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-62.2M | $-59.4M | $-42.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-62.2M | $-59.4M | $-42.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $65.5M | $47.3M | $40.5M |
| Cash & Equivalents | $49.4M | $36.8M | $27.8M |
| Inventory | $8.0M | $5.1M | $4.8M |
| Prepaid Expenses | $1.6M | $2.0M | $2.3M |
| Other Current Assets | $6.6M | $3.4M | $5.7M |
| Long-Term Assets | $53.7M | $49.1M | $78.4M |
| PP&E (Net) | $788.0K | $899.0K | $709.0K |
| Intangibles | $9.9M | $5.4M | $18.8M |
| Goodwill | $41.6M | $41.6M | $57.4M |
| Operating Leases | $1.2M | $967.0K | $1.1M |
| Other LT Assets | $117.0K | $149.0K | $392.0K |
| Total Assets | $119.2M | $96.4M | $118.9M |
| Current Liabilities | $19.4M | $12.5M | $16.6M |
| Current Debt | — | $4.0M | $5.5M |
| Current Leases | $293.0K | $111.0K | $504.0K |
| Deferred Revenue | $1.3M | $997.0K | $1.6M |
| Other Current Liab | $15.6M | $5.2M | $7.2M |
| Long-Term Liabilities | $19.8M | $25.8M | $30.2M |
| Long-Term Debt | $18.1M | $24.6M | $23.5M |
| LT Operating Leases | $827.0K | $885.0K | $765.0K |
| Other LT Liab | $910.0K | $276.0K | $6.0M |
| Total Liabilities | $39.2M | $38.2M | $46.9M |
| Shareholders' Equity | $80.0M | $58.1M | $72.0M |
| Paid-In Capital | $365.8M | $407.5M | $462.4M |
| Retained Earnings | $-285.9M | $-349.4M | $-390.3M |
| Total L&E | $119.2M | $96.4M | $118.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-62.2M | $-59.4M | $-42.7M |
| Non-Cash Adjustments | $11.2M | $37.1M | $11.5M |
| Working Capital Changes | $3.2M | $-8.0M | $-7.3M |
| Cash from Operations | $-47.8M | $-30.4M | $-38.6M |
| Capital Expenditures | $442.0K | $584.0K | $138.0K |
| Cash from Investing | $-573.0K | $-547.0K | $-8.9M |
| Debt Repayments | — | $27.8M | — |
| Share Buybacks | $134.0K | — | — |
| Cash from Financing | $61.9M | $18.3M | $38.5M |
| FX Effect | $0 | $0 | $-68.0K |
| Net Change in Cash | $13.5M | $-12.7M | $-9.0M |
| Beginning Cash | $35.9M | $49.5M | $36.8M |
| Ending Cash | $49.5M | $36.8M | $27.8M |
Frequently Asked Questions
How does DarioHealth Corp. make money?
The company's revenue is primarily derived from licensing its proprietary AI algorithms for specific anatomical regions and disease states, such as breast cancer detection and lung nodule analysis. A significant portion of operating expenses, particularly in research and development ($24.2M), indicates a focus on continuous algorithm refinement and the expansion of indications beyond initial approvals. The data suggests a software-as-a-service model where recurring licensing fees generate revenue while heavy non-cash adjustments reflect significant intangible asset amortization from past acquisitions.
What are the main risks for DRIO?
The company faces significant revenue volatility and contraction risks, as evidenced by a 34% drop in revenue from 2022 to 2023 before recovering partially in 2024. Persistent net losses exceeding $40M annually raise concerns about long-term cash burn and the ability to sustain operations without substantial external financing. High levels of goodwill ($57.4M) accumulated from acquisitions expose the company to potential impairment charges if synergies fail to materialize or integration costs escalate. Regulatory changes in healthcare data privacy or AI approval processes could disrupt current licensing models and delay product launches.
What is DRIO's competitive advantage?
DRIO possesses a robust proprietary dataset built from years of clinical collaboration, enabling its AI models to achieve superior accuracy and generalizability compared to competitors. The company has established strong strategic partnerships with major healthcare systems, creating high switching costs and deep integration into existing radiology workflows that protect market share. Its agile engineering team allows for rapid iteration on software updates, ensuring the product remains at the cutting edge of medical imaging technology without requiring hardware deployment.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.